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MELODIC INTONATION THERAPY IMPROVES COMMUNICATION IN 
POSTSTROKE NONFLUENT APHASIA: A RANDOMISED PILOT TRIAL 
 
ABSTRACT  
Objective: To collect data to estimate the sample size of a definitive randomised 
clinical trial to evaluate the effects of Melodic Intonation Therapy in poststroke 
nonfluent aphasia.  
Design: A randomised, crossover, interventional pilot trial.  
Setting: Departments of Neurology and Rehabilitation from a university general 
hospital.  
Participants: Stroke survivors with poststroke nonfluent aphasia.  
Interventions: Patients randomised to group 1 had treatment with Melodic Intonation 
Therapy first (12 sessions over 6 weeks) followed by no treatment; the patients in 
group 2 started active treatment between 3 and 6 months after their inclusion in the 
study, serving as waiting list controls for the first phase.  
Main measures: The Communicative Activity Log (CAL) questionnaire and the 
Boston Diagnostic Aphasia Examination (BDAE) were evaluated at baseline, and at 6 
and 12 weeks.  
Results: Twenty patients were included. Four of the patients allocated to group 2 
crossed over to group 1, receiving the treatment at first. Intention-to-treat analysis: after 
adjustment for baseline scores, the mean difference in the CAL evaluation from baseline 
in the treated group was 8.5 points (95% CI, 0.11–17.0; P=.043), with no significant 
change in any of the BDAE sections. Per protocol analysis showed similar results with a 
clear treatment effect (P=.043) on the CAL.  
Conclusions: Melodic Intonation Therapy might have a positive effect on the 
communication skills of stroke survivors with nonfluent aphasia as measured by the 
CAL questionnaire. A full-scale trial with at least 27 patients per group is necessary to 
confirm these results. 
 
 
































































MELODIC INTONATION THERAPY IN POSTSTROKE NONFLUENT 
APHASIA: A RANDOMISED PILOT TRIAL 
 
INTRODUCTION 
According to a Cochrane meta-analysis, speech and language therapy for people with 
poststroke aphasia is beneficial in terms of improved functional communication, 
reading, writing and expressive language, compared with no therapy [1]. However, the 
supporting evidence is weak; two main challenges being the wide heterogeneity in the 
speech and language therapies used in clinical trials and the small sample size of the 
majority of them, thus preventing the recommendation of a specific therapy. In fact, at 
least 20 different therapeutic approaches were reported within the 74 randomised 
clinical trials included in the Cochrane meta-analysis, and the median sample size was 
30 patients [1]. 
Melodic Intonation Therapy [2] is a language therapy proposed to improve aphasia after 
stroke; although evidence for its efficacy from randomised clinical trials is still scarce 
[1]. Melodic Intonation Therapy has been proposed for selected patients, particularly 
those with significant defects in language production, poor verbal agility, relatively 
preserved repetition and poor understanding (i.e., essentially patients with nonfluent 
aphasia) [2,3]. It is based on the use of musical elements of speech (rhythm and melody) 
to improve language production by engaging language-capable regions in the 
undamaged right hemisphere of the brain [4]. Patients with aphasia are trained to keep 
the beat of oral statements that are initially sung by the therapist; the patient then 
attempts to reproduce these statements whilst keeping the intonation and the beat. As 
the therapy progresses, the therapist eliminates the stimulation and the patient must 
produce the item independently and with their usual prosody.  
































































It has been hypothesised that Melodic Intonation Therapy can promote both functional 
and structural brain plasticity, and the proposed mechanisms for its therapeutic effect 
are the activation of language-capable regions of the right cerebral hemisphere and the 
promotion of left perilesional activation. Some neuroimaging studies support both 
hypotheses [5–7].  
To improve the generalised use of this speech therapy, adaptations to other languages, 
such as French, Italian and Portuguese (Brazil), have already been successfully 
completed [8–10]. We recently reported the development of a Spanish adaptation of 
Melodic Intonation Therapy that includes commonly used phrases in the patient’s 
environment, and we explored its feasibility for use in a nonrandomised small study 
including four patients with nonfluent poststroke aphasia [11]. It is necessary, however, 
to perform a larger prospective study to demonstrate the benefits of this therapy in 
improving aphasia outcome. Due to the paucity of data on the effectiveness of this 
therapy, it appears necessary to conduct a pilot trial to collect data to estimate the 
sample size of a definitive randomised clinical trial [12].  
 
METHODS 
Design: This was a randomised pilot study developed by the Departments of Neurology 
and Rehabilitation (Speech Therapy Unit) of a stroke centre at a university general 
hospital, with the aim of collecting data to estimate the sample size of a definitive 
randomised clinical trial. The study was conducted according to the recommendations 
of the Helsinki Declaration and Good Clinical Practice guidelines and was approved by 
the La Paz University Hospital Ethics Committee for Clinical Research (Code HULP-PI 
894). It has been registered at the Clinical Trials Government website with the trial 
number NCT3433495.  
































































Our first step, already published, was to develop a Spanish adaptation of Melodic 
Intonation Therapy that included commonly used phrases in the patient’s environment 
and to explore the feasibility of the Spanish adaptation of this language therapy in a 
nonrandomised trial including four patients with nonfluent poststroke aphasia [11]. We 
then developed a randomised, crossover, interventional pilot trial in a different set of 
patients. Recruitment started in September, 2012 and ended in February, 2016.  
 
Patients: The patients were recruited from the outpatient clinic at the Department of 
Neurology and Stroke Centre of La Paz University Hospital as well as the Speech 
Therapy Unit from the Department of Rehabilitation. We included patients diagnosed 
with nonfluent aphasia due to unilateral stroke in the left hemisphere, without 
neuroimaging evidence of lesions in the right hemisphere, who fulfilled the following 
criteria:  
• The time elapsed since the stroke exceeded 6 months.  
• The patient had received a standard program of conventional speech therapy 
after stroke. 
• The patient had persistent nonfluent aphasia with the following characteristics 
[3]:  
o Severely restricted language, which might be limited to meaningless 
stereotypy; unlike that observed in verbal tasks, the patient might 
produce some real and relevant words when singing familiar songs. 
o Poor repetition, even for single words. 
o Moderately preserved language comprehension. 
o The nonstereotyped language was produced with a slurring of speech. 
































































o The total score for the repetition did not exceed the 70th percentile in the 
Boston Diagnostic Aphasia Examination [13]. The score was obtained 
from the average score in two areas: repetition of words and phrases.  
o Listening comprehension must exceed the 15th percentile of the Boston 
Diagnostic Aphasia Examination, from the average score obtained in 
another three areas: word comprehension, commands and complex 
ideational material. 
• Signed informed consent was provided. 
We excluded patients with a history of previous stroke other than the index event or 
with any clinical condition (e.g., short life expectancy, coexisting disease) or other 
characteristics that precluded appropriate follow-up in the study; those who were 
participating in any therapeutic interventional clinical trials evaluating poststroke 
recovery; and those using psychotropic drugs that interfere with patient evaluation. 
 
Sample size: Given this was a pilot study, a formal sample size calculation was not 
required. However, by using the free online sample size and power calculator 
GRANMO tool (version 7.12, April 2012) developed by the Municipal Institute for 
Medical Research (Barcelona, Spain) [14,15], and the data obtained on the four patients 
evaluated in the prior nonrandomised feasibility study, we estimated a sample size of 20 
patients, accepting an alpha risk of 0.05 and a beta risk of 0.2. The minimum difference 
to be detected was 0.1 and the standard deviation was 0.15.  
 
Study groups: Upon signature of informed consent, the included patients were randomly 
allocated to one of the following groups according to the period in which they received 
the Melodic Intonation Therapy (Figure 1):  
































































a) Group 1: For whom Melodic Intonation Therapy was planned to start within the 
first 3 months of their inclusion in the study, with a subsequent period of 3 
months without therapy (washout period). 
b) Group 2: Melodic Intonation Therapy was delayed to start between 3 and 6 
months after their inclusion in the study, without receiving speech therapy 
treatment in the first 3 months, thus serving as controls for the first phase of the 
study (waitlist controls) and as the active intervention group in the second phase.  
A computer-generated random list of numbers provided by an independent statistician 
was used for study allocation. Allocation was simple, with a 1:1 ratio. The patients were 
consecutively allocated to the next available number on the randomization list, as long 




The duration of therapy was 12 sessions performed over a 6-week period. Each session 
lasted 30 minutes. They were performed individually by a speech-experienced therapist 
previously trained in Melodic Intonation Therapy. We used the Melodic Intonation 
Therapy protocol adapted to Spanish [11]; in brief, three levels with 20 items in each 
level were established. Within each level, the items were ordered such that intonation 
intervals alternated and the difficulty level was progressive. All the items were 
reinforced with images and hand tapping. 
 
Assessment of treatment outcomes 
A neuropsychologist blinded to the group to which the patient was allocated evaluated 
the Boston Diagnostic Aphasia Examination [13] three times for each patient: at 
baseline, and at 6 and 12 weeks, as shown in Figure 1. The Boston Diagnostic Aphasia 
































































Examination was chosen to evaluate the effects of Melodic Intonation Therapy 
following the instructions in the Melodic Intonation Therapy manual [3]. In addition, 
the Communicative Activity Log questionnaire [16] was completed by the caregiver. 
This measurement was chosen to obtain information about the amount and quality of 
communication in the real-world setting and has been used in other randomised clinical 
trials evaluating speech therapies [17,18]. 
 
Statistical analysis 
The analyses were performed using SAS 9.3 (SAS Institute, Cary, NC, USA). Data 
were expressed as median and interquartile range or mean and standard deviation for the 
continuous variables, or as absolute and relative frequencies for the categorical 
variables. To evaluate the benefit of Melodic Intonation Therapy on the Communicative 
Activity Log and Boston Diagnostic Aphasia Examination questionnaires, we used 
mixed effects linear regression models. A mixed effects linear regression model is 
a statistical model particularly useful for longitudinal studies in which repeated 
measurements are analysed. Because of their advantage in dealing with missing values, 
mixed effects models are usually preferred over other approaches, such as the repeated 
measures ANOVA, allowing for an adjustment of the treatment effects by the baseline 
values and the period effect in crossover trials. 
Given this study has a crossover design with two treatment sequences (treatment-
washout/waitlist-treatment) and two phases (phase 1 and phase 2) with a baseline 
evaluation of all the patients, we considered treatment and phase as principal fixed 
effects, the treatment*phase as interaction effect and the patient nested in the treatment 
sequence as random effect. The baseline evaluation was analysed as a covariant in the 
models. For pair-wise post hoc comparisons, we used the Bonferroni test. Finally, for 
































































the calculation of the sample size needed for a definitive trial we used N Query advisor 





A total of 36 patients were screened and evaluated by a specialist in neuropsychology, 
who administered the Boston Diagnostic Aphasia Examination. Twenty patients met the 
study criteria. All were right-handed, with ages ranging between 38 and 81 years. All 
were native Spanish speaking, and two also spoke another language (French). All the 
patients had had an ischaemic stroke in the territory of the left middle cerebral artery 
with persisting moderate-to-severe nonfluent aphasia or global aphasia. 
Figure 1 shows the study flow diagram according to the Consolidated Standards of 
Reporting of Trials guidelines [11,14]. Four of the 10 patients allocated to group 2 
crossed over to group 1, thus receiving the treatment at first, due to the inability of some 
patients to attend the treatment on the dates of the assigned group. For this reason, we 
are providing the results of the intention-to-treat (comparison of the treatment groups 
that includes all patients as originally allocated after randomization), as well as the per-
protocol analysis (in which the four patients who crossed over to the first Melodic 
Intonation Therapy treatment and completed the treatment without any other deviation 
from protocol were analysed in the early treatment group) (Table 2). One patient 
allocated to group 1 dropped out of the study early due to a severe concomitant disease.  
 
Intention-to-treat analysis  
No differences were found in baseline characteristics between study groups (Table 1), 
nor in baseline scores in the neuropsychological evaluations (Table 2). Mixed effects 
linear models showed no significant treatment effects in the evaluation of either the 
































































Boston Diagnostic Aphasia Examination-comprehension test (P=.925) or the Boston 
Diagnostic Aphasia Examination-repetition test (P=.727). Finally, the mixed effects 
linear regression models for Communicative Activity Log evaluation showed a clear 
treatment effect (P=.019) and period effects (P=.019) as well as a positive correlation 
with baseline values (coefficient=0.2; P=.006). After adjustment for baseline scores, the 
mean difference in the Communicative Activity Log evaluation from baseline in the 
treated group was 8.5 points (95% CI, 0.11–17.00; P=.048). 
 
Per protocol analysis  
No differences were found in baseline characteristics between study groups (Table 1), 
nor in baseline scores in the neuropsychological evaluations (Table 2). At the end of 
phase 1, however, group 1 (which received early Melodic Intonation Therapy) showed 
significantly higher values in the Communicative Activity Log, with no significant 
change in any of the Boston Diagnostic Aphasia Examination sections. At the end of 
phase 2, the values of the Communicative Activity Log test in group 2 also increased 
after Melodic Intonation Therapy, reaching values s milar to those of group 1, which 
had been treated early. Fixed-effects linear models sho ed no significant treatment 
effect in the evaluation of the Boston Diagnostic Aphasia Examination-comprehension 
test (P=.460) nor in the Boston Diagnostic Aphasia Examination-repetition test 
(P=.995). Similarly to the intention-to-treat analysis, the fixed effect linear regression 
models for the Communicative Activity Log evaluation showed a clear treatment effect 
with a similar magnitude to that of the intention-to-treat analysis (mean difference 7.2 
points (95% CI, 0.34–17.55; P=.043). 
 
Sample size calculation for a definitive trial  
































































Using the data on the standard deviation of the main change in the Communicative 
Activity Log evaluation after Melodic Intonation Therapy, for a definitive randomised, 
double-blind, parallel clinical trial we would need a sample size of 27 patients in each 
arm for an 80% power and a 0.050 two-sided significance level.  
 
DISCUSSION  
This small, randomised, clinical pilot trial suggests that Melodic Intonation Therapy 
could have a positive effect on the communication skills of stroke survivors with 
nonfluent aphasia as measured by the Communicative Activity Log questionnaire [16]. 
This effect appears early after therapy administration and remains at 3 months after the 
end of treatment. Few clinical trials have evaluated the efficacy of Melodic Intonation 
Therapy on poststroke aphasia. Conklyn et al. developed a pilot study in patients who 
had acute stroke, showing the feasibility of this therapy for in-hospital patients, as well 
as the significant improvements in responsiveness scores compared with controls [20]. 
Van der Meulen et al. conducted two randomised clinical trials evaluating the effect of 
Melodic Intonation Therapy: within the first 2–3 months after stroke [21] and after 1 
year [22]. Within the first 2–3 months after stroke, Melodic Intonation Therapy 
improved repetition of trained and untrained tasks [21]. However, in patients with 
severe aphasia more than 1 year poststroke, despite Melodic Intonation Therapy having 
been associated with a significantly improved repetition of trained tasks, the effect did 
not remain stable at the follow-up assessment [22].  
There is some heterogeneity in the outcome evaluations used in the various clinical 
trials published to date assessing the efficacy of Melodic Intonation Therapy in 
poststroke aphasia. Some have evaluated modified responsive and repetition subsections 
of the Western Aphasia Battery [20], whereas others [16,17] used the Sabadel story 
































































retelling task, measuring information content in connected speech [23]; the Amsterdam 
Nijmegen Everyday Language Test, measuring verbal communication in daily life [24]; 
the Aachen Aphasia Test [25], with the repetition and naming subtests; and the Melodic 
Intonation Therapy repetition task [3]. The positive effects of Melodic Intonation 
Therapy have been shown in all except for the Sabadel task. Our study shows that 
Melodic Intonation Therapy is also useful for improving communication as measured 
by the Communicative Activity Log questionnaire [16]. This test has been shown to be 
useful for evaluating the effects of other speech therapies, such as constraint-induced 
aphasia therapy in clinical trials [16–18].  
Our study has several limitations. First, the sample size was small and therefore 
underpowered to obtain firm conclusions. The study was designed as a pilot trial aimed 
to obtain data that could allow us to estimate the needed sample size for a further 
definitive randomised clinical trial focused on efficacy. Nevertheless, the total number 
of included patients is within the frame of prior randomised clinical trials published to 
date evaluating the efficacy of Melodic Intonation Therapy, ranging between 17 and 30 
patients [20–22]. Although we achieved the precalculated sample size, one patient 
dropped out early due to the development of a severe concomitant disease and three 
other patients did not attend the final visit, resulting in a 20% dropout rate. An 
additional limitation was that four patients allocated to group 2 crossed over to group 1 
due to the inability to attend the treatment on the dates corresponding to the assigned 
group. To prevent this from affecting the results, we provide the results of the ITT and 
the per-protocol analysis. In both analyses, the positive effect of Melodic Intonation 
Therapy on communication skills was suggested. 
Another important problem was the long time required for the recruitment of patients, 
mainly due to the low prevalence of chronic severe nonfluent poststroke aphasia and to 
































































the requirement of our study that patients should have completed the available standard 
speech therapy to avoid the ethical conflict of offering an investigational therapy with 
unknown efficacy, excluding them from the conventional speech therapy. Therefore our 
study was restricted to the inclusion of chronic aphasias resistant to standard speech 
therapy, therefore limiting the generalisation of our results. However, to progress to a 
definitive clinical trial, it would be feasible to modify that inclusion criterion allowing 
recruiting patients at earlier post-stroke stages, given Melodic Intonation Therapy has 
been shown to be feasible and beneficial in earlier stages, such as at acute stroke 
hospitalization [20], as well as within the first 2–3 months after stroke [21]. This 
modification would likely esult in an easier recruitment of the needed sample size of 27 
patients per group based on our calculations, as well in lower dropout rates.   
 Our main strength is the design as a crossover, randomised clinical trial, thus allowing 
more patients to be treated, and the ability to evaluate not only the early effect of 
Melodic Intonation Therapy, but also to assess the stability of the improvement in 
communication skills obtained by Melodic Intonation Therapy at 12 weeks after the 
baseline evaluation. In addition, we adjusted the models to evaluate the possible 
interaction with the period of treatment. Although all the included patients showed a 
clear improvement from baseline to the follow-up evaluations, our results suggest a 
treatment effect of Melodic Intonation Therapy on communication skills. With these 
results, we were able to calculate the sample size for a definitive randomised double-
blind, parallel clinical trial to confirm the efficacy of this therapy in poststroke 
nonfluent aphasia.  
 
In conclusion, this small, randomised pilot trial suggests that Melodic Intonation 
Therapy could have a positive effect on the communication skills of stroke survivors 
































































with nonfluent aphasia as measured by the CAL questionnaire. A full-scale trial with at 
least 27 patients per group is necessary to confirm these results.  
 
Clinical messages:  
• This small, randomised pilot clinical trial suggests that Melodic Intonation 
Therapy could have a positive effect on the communication skills of stroke 
survivors with nonfluent aphasia as measured by the Communicative Activity 
Log questionnaire. A full-scale trial with at least 27 patients per group is 
necessary to confirm these results. 
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Figure Legend  







































































Table 1. Baseline characteristics. Per-protocol population. 
 
 Intention-to-treat population* Per-protocol population** 









Demographic characteristics and time from stroke 
Age, mean (SD) 66.9 (14.7) 61.1 (14.1) .364 65.2 (15.1) 61.7 (13.3) .659 
Male sex, N (%) 6 (60) 6 (60) .675 10 (71.4) 2 (33.3) .137 



























Bilingual, N (%) 0 (0) 2 (20) .237 2 (14.3) 0 (0) .479 
Time from stroke onset (months), median (IQR) 21.8 (17.5) 27.7 (18) .462 16 (9, 36.5) 20.5 (14.7, 37) .966 
Prior standard speech therapy 
Time from prior standard speech therapy (months), median 
(IQR)  
0 (0, 0) 1.5 (0, 7.7) .085 0 (0, 0) 5 (0, 11.5) .800 
Duration (weeks), mean (SD) 49.7 (37.1) 87.2 (80.6) .480 72.6 (68.3) 57.8 (55.8) .633 
IQR: interquartile range; SD: standard deviation. *Intention-to treat population: all the patients are included in the group as originally allocated 
after randomisation regardless of whether they crossed over to the other group. ** Per-protocol population: includes the four patients who 
crossed over in the early treatment group (group 1).  
  
































































Table 2. Outcome evaluations. 
 Boston Diagnostic Aphasia Examination -
Comprehension, mean (SD) 
Boston Diagnostic Aphasia Examination –
Repetition, mean (SD) 
Communicative Activity Log 
Baseline End of Phase 1 
(6 weeks after 
baseline) 
End of Phase 2 
(12 weeks after 
baseline) 
Baseline End of Phase 1 
(6 weeks after 
baseline) 
End of Phase 2 
(12 weeks after 
baseline) 
Baseline End of Phase 1 
(6 weeks after 
baseline) 
End of Phase 2 
(12 weeks after 
baseline) 











36.1 (32.1) 36.1 (19.2) 39.4 (26.9) 47.1 (28.5) 53.9 (27) 62.8 (28.2) 112.2 (20) 117 (23.3) 123.6 (14) 














46.9 (37.2) 40 (22.3) 48.6 (26.4) 49.1 (29.6) 48.3 (30.2) 52.5 (25.7) 106 (12.3) 111.2 (20.7) 123.7 (16.2) 
P-value‡ .861 .460 .429 .995 .460 .043 
SD: standard deviation. *Intention-to treat analysis: all the patients are included in the group as originally allocated after randomisation 
regardless of whether they crossed over to the other group. ** Per-protocol population: the four patients who crossed over to the early treatment 
group are analysed as belonging to Group 1. ‡ P-value in cells of end of phase 1 and 2 corresponds to the treatment effect adjusted by the 
baseline values and the treatment period. 
































































Figure 1. Flow diagram. 
 
 
 Assessed for eligibility (n=36) 
Not meeting inclusion criteria after 
neuropsychologist evaluation (n=16) 
Analysed (n=8) 
♦ Excluded from analysis (n=2; one early drop-
out due to severe disease and one patient due 
to inability to attend the final visit) 
Washout period 
Lost to follow-up (n=0)  
 
10 patients allocated to group 1 (early MIT)  
♦ Received allocated intervention (n=9) 
♦ Did not receive allocated intervention (n=1, 
due to a severe disease) 
Intervention (delayed MIT) 
Lost to follow-up (n=1 due to inability to attend 
the planned visit) 
10 patients allocated to group 2 (wait list)  
♦ Received allocated intervention (n=6) 
♦ Did not receive allocated intervention (n=4; 
all of them crossed over to Group 1 due to 
inability to attend the intervention on the 
assigned dates) 
Analysed (n=8) 
♦ Excluded from analysis (n=2, due to inability 






Evaluation 1 (Baseline) 
Final evaluation 







6 weeks from baseline 
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